Biomea's Oral GLP-1 Drug Shows Promise in Early Human Trials

Biomea Fusion has released promising Phase I results for its oral GLP-1 receptor antagonist, BMF-650. The data, unveiled in early 2025, showed strong tolerability and rapid absorption in healthy volunteers. Company leaders later discussed the findings in a private conference call for JPMorgan clients.

The Phase I study tested BMF-650 in healthy participants, with topline data arriving in 2025. Results confirmed no serious side effects, a peak absorption time of around one to two hours, and dose-proportional drug behaviour up to 200 mg. Early signs also pointed to effective GLP-1 suppression. Independent experts highlighted the drug's clean safety record and potential as an oral treatment.

Regulatory progress followed swiftly. In early 2026, the FDA granted Fast Track designation, indicating no major concerns with the compound's development path. On March 30, 2026, Biomea executives held a closed conference call to review the findings. Attendees included Interim CEO Michael J. Hitchcock, Research Head Thorsten Kirschberg, and President Ramses Erdtmann. Analysts Anupam Rama and Joyce Zhou from JPMorgan Chase & Co. joined the discussion, which was restricted to select clients only.

The Phase I success and Fast Track status position BMF-650 as a potential oral therapy for obesity. With no serious safety issues reported and rapid drug absorption confirmed, the next stages of clinical testing will determine its broader effectiveness. Biomea's leadership continues to engage with investors and regulators as development advances.